Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis

Clin Chim Acta. 2006 Nov;373(1-2):55-61. doi: 10.1016/j.cca.2006.04.026. Epub 2006 May 13.

Abstract

Background: The present study examined the effects of atorvastatin and the in vitro effect of apolipoprotein (apo) A-I/phosphatidylcholine (POPC) discs on charge-based triglyceride-rich lipoprotein (TRL) subfractions in a patient with type III hyperlipoproteinemia (HLP) and the apoE2/2 phenotype.

Methods: Charge-based lipoprotein subfractions were characterized by capillary isotachophoresis (cITP). cITP analysis was performed using plasma that had been prestained with a lipophilic dye on a Beckman P/ACE MDQ system.

Results: Treatment with atorvastatin for 4 weeks markedly decreased the slow (s)-migrating TRL subfraction and both fast- and slow-migrating low-density lipoprotein (LDL) subfractions, but did not affect the fast (f)-migrating TRL subfraction in this patient. ApoA-I/POPC discs consisted of two major charge-based subfractions that had the mobility of cITP fTRL and sTRL. Incubation of plasma from this patient in the presence of apoA-I/POPC discs caused not only a reduction in cITP fast- and intermediate-migrating HDL and an increase in cITP sHDL but also a reduction in fTRL and sTRL and an increase in sLDL.

Conclusion: Atorvastatin and apoA-I/POPC discs decreased cITP TRL subfractions in a complementary manner, suggesting that the combination of apoA-I/POPC discs and atorvastatin could be a promising therapeutic approach for hypertriglyceridemia.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Apolipoprotein A-I / chemistry*
  • Apolipoprotein A-I / pharmacology
  • Apolipoprotein E2 / genetics
  • Atorvastatin
  • Electrophoresis, Capillary / methods
  • Heptanoic Acids / administration & dosage
  • Heptanoic Acids / pharmacology*
  • Humans
  • Hyperlipoproteinemia Type III / blood
  • Hyperlipoproteinemia Type III / drug therapy*
  • Hyperlipoproteinemia Type III / genetics
  • Lipoproteins / blood
  • Lipoproteins / chemistry*
  • Lipoproteins / drug effects
  • Macromolecular Substances / chemistry
  • Macromolecular Substances / pharmacology
  • Male
  • Phenotype
  • Phosphatidylcholines / chemistry*
  • Phosphatidylcholines / pharmacology
  • Pyrroles / administration & dosage
  • Pyrroles / pharmacology*
  • Sensitivity and Specificity
  • Time Factors
  • Triglycerides / analysis*

Substances

  • Apolipoprotein A-I
  • Apolipoprotein E2
  • Heptanoic Acids
  • Lipoproteins
  • Macromolecular Substances
  • Phosphatidylcholines
  • Pyrroles
  • Triglycerides
  • Atorvastatin